American heart journal plus : cardiology research and practice最新文献

英文中文

An advanced vision of magnetocardiography as an unrivalled method for a more comprehensive non-invasive clinical electrophysiological assessment

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-23 DOI: 10.1016/j.ahjo.2025.100514

Riccardo Fenici , Marco Picerni , Peter Fenici , Donatella Brisinda

Decades of experimental and clinical studies, along with the most recent clinical trials, have demonstrated the diagnostic potential of magnetocardiography, particularly for the non-invasive early diagnosis of myocardial ischemia. It has also proven to be a valuable clinical tool for monitoring fetal well-being, normal growth, prenatal arrhythmias, and risk markers for sudden death. Such applications have recently received official recognition from Health Canada and the American Heart Association. This unquestionable success, and the additional evidence of magnetocardiography's high sensitivity in diagnosing infiltrative and inflammatory cardiomyopathies, has sparked renewed interest among clinicians.

However, while these aforementioned applications are likely to significantly influence the broader clinical adoption of magnetocardiography, the general focus on these areas has shifted attention away from what we have always regarded as the fundamental strength of contactless cardiac magnetic field mapping: its unique ability to bridge the gap between experimental electrophysiology at the cellular level and non-invasive clinical assessments of human electrophysiology.

This review aims to engage readers by sharing our vision, experience, and several key research milestones, emphasizing the lesser-explored yet significant potential of magnetocardiography. Specifically, it highlights its unique capability to detect electrically silent phenomena that may be critical for the timely and accurate identification of arrhythmogenic focal electrotonic and vortex currents, which can trigger or sustain life-threatening arrhythmias.

{"title":"An advanced vision of magnetocardiography as an unrivalled method for a more comprehensive non-invasive clinical electrophysiological assessment","authors":"Riccardo Fenici , Marco Picerni , Peter Fenici , Donatella Brisinda","doi":"10.1016/j.ahjo.2025.100514","DOIUrl":"10.1016/j.ahjo.2025.100514","url":null,"abstract":"<div><div>Decades of experimental and clinical studies, along with the most recent clinical trials, have demonstrated the diagnostic potential of magnetocardiography, particularly for the non-invasive early diagnosis of myocardial ischemia. It has also proven to be a valuable clinical tool for monitoring fetal well-being, normal growth, prenatal arrhythmias, and risk markers for sudden death. Such applications have recently received official recognition from Health Canada and the American Heart Association. This unquestionable success, and the additional evidence of magnetocardiography's high sensitivity in diagnosing infiltrative and inflammatory cardiomyopathies, has sparked renewed interest among clinicians.</div><div>However, while these aforementioned applications are likely to significantly influence the broader clinical adoption of magnetocardiography, the general focus on these areas has shifted attention away from what we have always regarded as the fundamental strength of contactless cardiac magnetic field mapping: its unique ability to bridge the gap between experimental electrophysiology at the cellular level and non-invasive clinical assessments of human electrophysiology.</div><div>This review aims to engage readers by sharing our vision, experience, and several key research milestones, emphasizing the lesser-explored yet significant potential of magnetocardiography. Specifically, it highlights its unique capability to detect electrically silent phenomena that may be critical for the timely and accurate identification of arrhythmogenic focal electrotonic and vortex currents, which can trigger or sustain life-threatening arrhythmias.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"52 ","pages":"Article 100514"},"PeriodicalIF":1.3,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143488207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a first of a kind robotic radiation protection technology to reduce scatter exposure during diagnostic procedures and percutaneous coronary interventions

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-21 DOI: 10.1016/j.ahjo.2025.100512

Wojciech E. Krzyzanowski, Pawel Radecki, Marta K. Szczerbińska, Kamil Dawidczyk, Mikołaj Kosek, Krzysztof Romanik, Wojciech Suchcicki, Dariusz Karwowski, Paweł R. Natkowski

Background

This study evaluated the effectiveness of the Radiaction system in providing comprehensive protection to medical personnel during fluoroscopy-guided procedures in an Interventional Cardiology (IC) laboratory. The system confines the imaging beam and blocks scatter radiation at its source, enhancing safety for the Cath lab staff.

Methods

A prospective, non-randomized, controlled study compared real-time procedures with and without Radiaction. Sensors were placed around the room and on the main physician to measure radiation exposure during 82 diagnostic and 24 interventional cases without the Radiaction system and 65 diagnostic and 39 interventional cases with Radiaction.

Results

Results demonstrated a significant reduction in radiation exposure with the Radiaction system. Across all cases, the overall reduction in radiation was 74.7 % for all sensor locations and 82.9 % for the main physician. Diagnostic procedures exhibited a reduction of 73 % with the Radiaction system and Interventional procedures demonstrated a 79 % reduction across all sensors with the Radiaction system. Calculations were conducted to estimate the reduction during the time that the system was deployed, revealing an 85.7 % reduction across all sensors and 95.1 % for the main physician, reflecting the full potential of the system when used during 100 % of the X-ray time. Users expressed high satisfaction with the system, citing its user-friendly nature, and seamless integration into clinical workflow.

Conclusions

The Radiaction system significantly reduced radiation exposure in all cases compared to cases conducted without Radiaction. These findings support the potential of the Radiaction system to offer full-body protection from scattered radiation to all medical personnel in the IC suite, emphasizing its value in enhancing occupational safety in medical environments.

{"title":"Evaluation of a first of a kind robotic radiation protection technology to reduce scatter exposure during diagnostic procedures and percutaneous coronary interventions","authors":"Wojciech E. Krzyzanowski, Pawel Radecki, Marta K. Szczerbińska, Kamil Dawidczyk, Mikołaj Kosek, Krzysztof Romanik, Wojciech Suchcicki, Dariusz Karwowski, Paweł R. Natkowski","doi":"10.1016/j.ahjo.2025.100512","DOIUrl":"10.1016/j.ahjo.2025.100512","url":null,"abstract":"<div><h3>Background</h3><div>This study evaluated the effectiveness of the Radiaction system in providing comprehensive protection to medical personnel during fluoroscopy-guided procedures in an Interventional Cardiology (IC) laboratory. The system confines the imaging beam and blocks scatter radiation at its source, enhancing safety for the Cath lab staff.</div></div><div><h3>Methods</h3><div>A prospective, non-randomized, controlled study compared real-time procedures with and without Radiaction. Sensors were placed around the room and on the main physician to measure radiation exposure during 82 diagnostic and 24 interventional cases without the Radiaction system and 65 diagnostic and 39 interventional cases with Radiaction.</div></div><div><h3>Results</h3><div>Results demonstrated a significant reduction in radiation exposure with the Radiaction system. Across all cases, the overall reduction in radiation was 74.7 % for all sensor locations and 82.9 % for the main physician. Diagnostic procedures exhibited a reduction of 73 % with the Radiaction system and Interventional procedures demonstrated a 79 % reduction across all sensors with the Radiaction system. Calculations were conducted to estimate the reduction during the time that the system was deployed, revealing an 85.7 % reduction across all sensors and 95.1 % for the main physician, reflecting the full potential of the system when used during 100 % of the X-ray time. Users expressed high satisfaction with the system, citing its user-friendly nature, and seamless integration into clinical workflow.</div></div><div><h3>Conclusions</h3><div>The Radiaction system significantly reduced radiation exposure in all cases compared to cases conducted without Radiaction. These findings support the potential of the Radiaction system to offer full-body protection from scattered radiation to all medical personnel in the IC suite, emphasizing its value in enhancing occupational safety in medical environments.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"52 ","pages":"Article 100512"},"PeriodicalIF":1.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143478864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The formation of cholesterol crystals and embolization during myocardial infarction

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-18 DOI: 10.1016/j.ahjo.2025.100509

Jamal Mughal , Venkat R. Katkoori , Stefan Mark Nidorf , Megan Manu , George S. Abela

Cholesterol crystals (CCs) released into the coronary circulation during plaque rupture have multiple adverse impacts on both the arterial conduit as well as the myocardium. CCs form within the atheromatous plaque by the saturation of free cholesterol deposition via facilitated LDL-c entry because of a dysfunctional endothelium. Once formed, CCs are viewed as a foreign body and activate inflammation via the innate immune system. Eventually, an inflamed atheromatous plaque ruptures by virtue of the growth and expansion of CCs that begin to occupy a greater volume than the liquid phase cholesterol. In some instances, the sharp edges of CCs can puncture and tear the plaque's fibrous cap causing rupture leading to thrombosis and myocardial infarction. In these circumstances, CCs are released from the ruptured plaque and travel down the coronary artery where they can scrape the endothelial lining which enhances vasospastic activity, further worsening ischemia. Moreover, when CCs lodge in the distal arteriolar and capillary beds, they not only obstruct blood flow to further aggravate ischemia but also activate an inflammatory response in the myocardium that leads to further tissue injury. Treatment of CCs has thus far been limited but studies using statins, aspirin and colchicine have demonstrated them to be effective in dissolving CCs that may provide additional benefits for both prevention and potentially for acute cardiovascular events.

斑块破裂时释放到冠状动脉循环中的胆固醇结晶（CC）会对动脉导管和心肌产生多种不利影响。由于内皮功能失调，游离胆固醇沉积饱和，促进低密度脂蛋白-c 进入动脉粥样斑块，从而形成 CC。一旦形成，CC 就会被视为异物，并通过先天性免疫系统激活炎症。最终，发炎的动脉粥样斑块会因开始占据比液相胆固醇更大体积的 CC 的生长和扩张而破裂。在某些情况下，CCs 的锋利边缘会刺穿并撕裂斑块的纤维帽，导致斑块破裂，从而引发血栓形成和心肌梗死。在这种情况下，CCs 会从破裂的斑块中释放出来，并沿着冠状动脉向下移动，在那里它们会刮伤血管内皮，从而增强血管痉挛活动，使缺血进一步恶化。此外，当CCs停留在远端动脉和毛细血管床时，它们不仅会阻碍血流，进一步加重缺血，还会激活心肌的炎症反应，导致组织进一步损伤。迄今为止，CCs 的治疗方法还很有限，但使用他汀类药物、阿司匹林和秋水仙碱进行的研究表明，它们能有效溶解 CCs，从而为预防和潜在治疗急性心血管事件提供额外的益处。

{"title":"The formation of cholesterol crystals and embolization during myocardial infarction","authors":"Jamal Mughal , Venkat R. Katkoori , Stefan Mark Nidorf , Megan Manu , George S. Abela","doi":"10.1016/j.ahjo.2025.100509","DOIUrl":"10.1016/j.ahjo.2025.100509","url":null,"abstract":"<div><div>Cholesterol crystals (CCs) released into the coronary circulation during plaque rupture have multiple adverse impacts on both the arterial conduit as well as the myocardium. CCs form within the atheromatous plaque by the saturation of free cholesterol deposition via facilitated LDL-c entry because of a dysfunctional endothelium. Once formed, CCs are viewed as a foreign body and activate inflammation via the innate immune system. Eventually, an inflamed atheromatous plaque ruptures by virtue of the growth and expansion of CCs that begin to occupy a greater volume than the liquid phase cholesterol. In some instances, the sharp edges of CCs can puncture and tear the plaque's fibrous cap causing rupture leading to thrombosis and myocardial infarction. In these circumstances, CCs are released from the ruptured plaque and travel down the coronary artery where they can scrape the endothelial lining which enhances vasospastic activity, further worsening ischemia. Moreover, when CCs lodge in the distal arteriolar and capillary beds, they not only obstruct blood flow to further aggravate ischemia but also activate an inflammatory response in the myocardium that leads to further tissue injury. Treatment of CCs has thus far been limited but studies using statins, aspirin and colchicine have demonstrated them to be effective in dissolving CCs that may provide additional benefits for both prevention and potentially for acute cardiovascular events.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"51 ","pages":"Article 100509"},"PeriodicalIF":1.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143454606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the quality of care for heart failure hospitalizations in inflammatory arthritis – A population-based cohort study

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-03 DOI: 10.1016/j.ahjo.2025.100503

Bindee Kuriya , Lihi Eder , Sahil Koppikar , Jessica Widdifield , Anna Chu , Jiming Fang , Irene Jeong , Douglas Lee , Jacob Udell

Background

Individuals with inflammatory arthritis (IA) face an elevated risk of heart failure (HF). However, whether the quality of HF care in IA patients differs from other high-risk groups, such as those with diabetes mellitus (DM), remains unclear.

Methods

This population-based cohort study in Ontario, Canada, included patients who experienced their first HF hospitalization and survived to discharge. Patients were categorized into four groups: IA alone, DM alone, IA + DM, and a general population comparator. We assessed quality care measures within 30 days of hospitalization (echocardiogram, electrocardiogram, chest x-ray) and physician follow-up within 7 days. Guideline-directed medical therapy (GDMT) adherence was evaluated within 90 days and classified as perfect, moderate, or poor. Logistic regression was used to determine whether IA was independently associated with lower HF care quality.

Results

Among 101,645 eligible hospitalizations, 1987 had IA + DM, 3849 had IA alone, 33,553 had DM alone, and 62,256 were general comparators. While all groups showed high adherence to testing, IA patients (with or without DM) had significantly lower GDMT use compared to DM patients (p < 0.001). IA was independently linked to lower odds of moderate or perfect GDMT adherence.

Conclusion

Although adherence to HF testing quality measures was high, IA patients were less likely to receive GDMT than those with DM. Further research is needed to understand the reasons for lower GDMT use in IA and its impact on HF outcomes such as re-hospitalization and mortality.

{"title":"Evaluating the quality of care for heart failure hospitalizations in inflammatory arthritis – A population-based cohort study","authors":"Bindee Kuriya , Lihi Eder , Sahil Koppikar , Jessica Widdifield , Anna Chu , Jiming Fang , Irene Jeong , Douglas Lee , Jacob Udell","doi":"10.1016/j.ahjo.2025.100503","DOIUrl":"10.1016/j.ahjo.2025.100503","url":null,"abstract":"<div><h3>Background</h3><div>Individuals with inflammatory arthritis (IA) face an elevated risk of heart failure (HF). However, whether the quality of HF care in IA patients differs from other high-risk groups, such as those with diabetes mellitus (DM), remains unclear.</div></div><div><h3>Methods</h3><div>This population-based cohort study in Ontario, Canada, included patients who experienced their first HF hospitalization and survived to discharge. Patients were categorized into four groups: IA alone, DM alone, IA + DM, and a general population comparator. We assessed quality care measures within 30 days of hospitalization (echocardiogram, electrocardiogram, chest x-ray) and physician follow-up within 7 days. Guideline-directed medical therapy (GDMT) adherence was evaluated within 90 days and classified as perfect, moderate, or poor. Logistic regression was used to determine whether IA was independently associated with lower HF care quality.</div></div><div><h3>Results</h3><div>Among 101,645 eligible hospitalizations, 1987 had IA + DM, 3849 had IA alone, 33,553 had DM alone, and 62,256 were general comparators. While all groups showed high adherence to testing, IA patients (with or without DM) had significantly lower GDMT use compared to DM patients (<em>p</em> < 0.001). IA was independently linked to lower odds of moderate or perfect GDMT adherence.</div></div><div><h3>Conclusion</h3><div>Although adherence to HF testing quality measures was high, IA patients were less likely to receive GDMT than those with DM. Further research is needed to understand the reasons for lower GDMT use in IA and its impact on HF outcomes such as re-hospitalization and mortality.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"51 ","pages":"Article 100503"},"PeriodicalIF":1.3,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Timing of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: A systematic review and meta-analysis

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-01 DOI: 10.1016/j.ahjo.2025.100506

Tanawat Attachaipanich , Suthinee Attachaipanich , Kotchakorn Kaewboot

Background

Acute myocardial infarction (AMI) complicated by cardiogenic shock has a high mortality rate. Mechanical circulatory support (MCS) has been increasingly used; however, the optimal timing for MCS insertion remains uncertain. This study aimed to evaluate outcomes of pre-percutaneous coronary intervention (PCI) vs post-PCI MCS insertion in AMI patients with cardiogenic shock.

Methods

A systematic search using 4 databases, including PubMed, Embase, Web of Science, and Cochrane CENTRAL, was conducted from inception to October 25, 2024. Studies comparing outcomes of MCS insertion pre-PCI vs post-PCI in this setting were included.

Results

There were 36 studies with a total of 6218 participants were included in this meta-analysis, using a random-effects model. Most of the included studies were non-randomized and retrospective. Early MCS insertion (prior to PCI) was associated with a lower risk of in-hospital mortality compared to late insertion (post-PCI), with an odds ratio (OR) of 0.46 (95%CI 0.36 to 0.57), p < 0.01. Subgroup analysis by MCS type (IABP, Impella, and ECMO) demonstrated that early insertion prior to PCI significantly reduced in-hospital mortality, regardless of the MCS type. Early MCS insertion prior to PCI was also associated with lower 30-day mortality (OR 0.62, (95%CI 0.43 to 0.89), p = 0.01) and 6-month mortality (OR 0.53, (95%CI 0.34 to 0.83), p = 0.01) compared to late insertion. There was no difference in 1-year mortality or in MCS-related complications.

Conclusions

Early MCS insertion prior to PCI is potentially associated with reduced in-hospital, 30-day, and 6-month mortality compared to post-PCI insertion in AMI patients with cardiogenic shock.

{"title":"Timing of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: A systematic review and meta-analysis","authors":"Tanawat Attachaipanich , Suthinee Attachaipanich , Kotchakorn Kaewboot","doi":"10.1016/j.ahjo.2025.100506","DOIUrl":"10.1016/j.ahjo.2025.100506","url":null,"abstract":"<div><h3>Background</h3><div>Acute myocardial infarction (AMI) complicated by cardiogenic shock has a high mortality rate. Mechanical circulatory support (MCS) has been increasingly used; however, the optimal timing for MCS insertion remains uncertain. This study aimed to evaluate outcomes of pre-percutaneous coronary intervention (PCI) vs post-PCI MCS insertion in AMI patients with cardiogenic shock.</div></div><div><h3>Methods</h3><div>A systematic search using 4 databases, including PubMed, Embase, Web of Science, and Cochrane CENTRAL, was conducted from inception to October 25, 2024. Studies comparing outcomes of MCS insertion pre-PCI vs post-PCI in this setting were included.</div></div><div><h3>Results</h3><div>There were 36 studies with a total of 6218 participants were included in this meta-analysis, using a random-effects model. Most of the included studies were non-randomized and retrospective. Early MCS insertion (prior to PCI) was associated with a lower risk of in-hospital mortality compared to late insertion (post-PCI), with an odds ratio (OR) of 0.46 (95%CI 0.36 to 0.57), <em>p</em> < 0.01. Subgroup analysis by MCS type (IABP, Impella, and ECMO) demonstrated that early insertion prior to PCI significantly reduced in-hospital mortality, regardless of the MCS type. Early MCS insertion prior to PCI was also associated with lower 30-day mortality (OR 0.62, (95%CI 0.43 to 0.89), <em>p</em> = 0.01) and 6-month mortality (OR 0.53, (95%CI 0.34 to 0.83), p = 0.01) compared to late insertion. There was no difference in 1-year mortality or in MCS-related complications.</div></div><div><h3>Conclusions</h3><div>Early MCS insertion prior to PCI is potentially associated with reduced in-hospital, 30-day, and 6-month mortality compared to post-PCI insertion in AMI patients with cardiogenic shock.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"50 ","pages":"Article 100506"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143172947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protein C deficiency with recurrent systemic thrombosis associated with compound heterozygous PROC missense variants

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-01 DOI: 10.1016/j.ahjo.2024.100496

Mikio Shiba , Shuichiro Higo , Yu Morishita , Yasuhiro Ichibori , Yoshihiro Kin , Yasushi Sakata , Yoshiharu Higuchi

Herein, we identified compound heterozygous PROC missense variants in a protein C deficient patient with recurrent thrombotic events, including intestinal necrosis, extrahepatic portal vein obstruction, and lower limb venous thrombosis. The patient's protein C activity and antigen levels were extremely low (<10 % and 5 %, respectively). Exome sequencing analysis revealed two rare missense variants (c.76G>A:p.Val26Met in exon 3 and c.1000G>A:p.Gly334Ser in exon 9), both confirmed to be associated with protein C deficiency and one synonymous variant (c.423G>T:p.Ser141Ser in exon 6) in PROC. PCR amplification of genomic DNA spanning these exons followed by Sanger sequencing analysis revealed that the c.76G>A and the synonymous c.423G>T variants were in the same allele, whereas the c.1000G>A variant was on the opposite allele, indicating compound heterozygosity. Western blot analysis of Huh-7 and HEK293T cells transfected with expression vectors encoding PROC with or without these variants demonstrated that Gly334Ser-PROC expression levels were significantly decreased in culture media collected from HEK293T cells, while the expression levels of protein C with these variants were not significantly altered in cell lysates. This suggests that these variants may affect both protein activity and the secretory process of protein C.

{"title":"Protein C deficiency with recurrent systemic thrombosis associated with compound heterozygous PROC missense variants","authors":"Mikio Shiba , Shuichiro Higo , Yu Morishita , Yasuhiro Ichibori , Yoshihiro Kin , Yasushi Sakata , Yoshiharu Higuchi","doi":"10.1016/j.ahjo.2024.100496","DOIUrl":"10.1016/j.ahjo.2024.100496","url":null,"abstract":"<div><div>Herein, we identified compound heterozygous <em>PROC</em> missense variants in a protein C deficient patient with recurrent thrombotic events, including intestinal necrosis, extrahepatic portal vein obstruction, and lower limb venous thrombosis. The patient's protein C activity and antigen levels were extremely low (<10 % and 5 %, respectively). Exome sequencing analysis revealed two rare missense variants (c.76G>A:p.Val26Met in exon 3 and c.1000G>A:p.Gly334Ser in exon 9), both confirmed to be associated with protein C deficiency and one synonymous variant (c.423G>T:p.Ser141Ser in exon 6) in <em>PROC</em>. PCR amplification of genomic DNA spanning these exons followed by Sanger sequencing analysis revealed that the c.76G>A and the synonymous c.423G>T variants were in the same allele, whereas the c.1000G>A variant was on the opposite allele, indicating compound heterozygosity. Western blot analysis of Huh-7 and HEK293T cells transfected with expression vectors encoding <em>PROC</em> with or without these variants demonstrated that Gly334Ser-PROC expression levels were significantly decreased in culture media collected from HEK293T cells, while the expression levels of protein C with these variants were not significantly altered in cell lysates. This suggests that these variants may affect both protein activity and the secretory process of protein C.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"50 ","pages":"Article 100496"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143172987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The design and rationale of the cardiac REHABilitation to improve metabolic health in Hypertrophic CardioMyopathy (REHAB-HCM) Study

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-01 DOI: 10.1016/j.ahjo.2025.100501

Matthew Cheung , Nathaniel Moulson , Jinelle C. Gelinas , Ali Daraei , Sarah M. Bradwell , Carolyn Taylor , Neil D. Eves , Graeme J. Koelwyn , Thomas M. Roston

Study objective

Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disorder increasingly characterized by concomitant metabolic syndrome. Cardiac rehabilitation (CR) has been shown to improve metabolic parameters in populations with heart failure and myocardial infarction. However, there is a paucity of data on the impact of CR in the HCM population with metabolic syndrome. We designed the REHAB-HCM study to explore the feasibility, safety, and efficacy of CR in HCM patients with metabolic syndrome.

Design

Prospective observation cohort study.

Setting

A multi-disciplinary HCM clinic and Multidisciplinary Exercise-based Cardiac Rehabilitation program.

Participants

Patients aged 18–80 years old diagnosed with HCM and metabolic syndrome, defined by the American Heart Association and American College of Cardiology guidelines, and the National Cholesterol Education Adult Treatment Panel III (NCEP-ATP III) criteria.

Intervention

A structured 3-month CR program with 6 months extended follow-up of physical activity levels.

Main outcome measures

Feasibility (e.g., attendance), safety (e.g., major adverse events and exercise-related harms), and efficacy pertaining to long term improvements in physical activity levels, metabolic health, cardiorespiratory fitness, quality of life, and systemic and cellular markers of inflammation.

Conclusion

This prospective cohort study will address an important knowledge gap by evaluating the effect of an organized CR program in HCM patients and metabolic syndrome. It is anticipated that exercise and CR will be feasible and beneficial for this complex patient population without significant exercise-related harms.

{"title":"The design and rationale of the cardiac REHABilitation to improve metabolic health in Hypertrophic CardioMyopathy (REHAB-HCM) Study","authors":"Matthew Cheung , Nathaniel Moulson , Jinelle C. Gelinas , Ali Daraei , Sarah M. Bradwell , Carolyn Taylor , Neil D. Eves , Graeme J. Koelwyn , Thomas M. Roston","doi":"10.1016/j.ahjo.2025.100501","DOIUrl":"10.1016/j.ahjo.2025.100501","url":null,"abstract":"<div><h3>Study objective</h3><div>Hypertrophic cardiomyopathy (HCM) is the most common genetic myocardial disorder increasingly characterized by concomitant metabolic syndrome. Cardiac rehabilitation (CR) has been shown to improve metabolic parameters in populations with heart failure and myocardial infarction. However, there is a paucity of data on the impact of CR in the HCM population with metabolic syndrome. We designed the REHAB-HCM study to explore the feasibility, safety, and efficacy of CR in HCM patients with metabolic syndrome.</div></div><div><h3>Design</h3><div>Prospective observation cohort study.</div></div><div><h3>Setting</h3><div>A multi-disciplinary HCM clinic and Multidisciplinary Exercise-based Cardiac Rehabilitation program.</div></div><div><h3>Participants</h3><div>Patients aged 18–80 years old diagnosed with HCM and metabolic syndrome, defined by the American Heart Association and American College of Cardiology guidelines, and the National Cholesterol Education Adult Treatment Panel III (NCEP-ATP III) criteria.</div></div><div><h3>Intervention</h3><div>A structured 3-month CR program with 6 months extended follow-up of physical activity levels.</div></div><div><h3>Main outcome measures</h3><div>Feasibility (e.g., attendance), safety (e.g., major adverse events and exercise-related harms), and efficacy pertaining to long term improvements in physical activity levels, metabolic health, cardiorespiratory fitness, quality of life, and systemic and cellular markers of inflammation.</div></div><div><h3>Conclusion</h3><div>This prospective cohort study will address an important knowledge gap by evaluating the effect of an organized CR program in HCM patients and metabolic syndrome. It is anticipated that exercise and CR will be feasible and beneficial for this complex patient population without significant exercise-related harms.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"50 ","pages":"Article 100501"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can utilization of the venous-to-arterial carbon dioxide difference improve patient outcomes in cardiogenic shock? A narrative review

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-01 DOI: 10.1016/j.ahjo.2025.100504

Oskar Kjærgaard Hørsdal

Cardiogenic shock (CS) is a critical condition with high mortality, characterized by reduced cardiac output (CO) and tissue hypoperfusion, despite advancements in treatment. Traditional hemodynamic markers like CO measurements, monitoring of mixed venous oxygen saturation (SvO₂) and lactate levels have limitations, particularly in detecting microcirculatory dysfunction. The venous-to-arterial carbon dioxide tension difference (V-A PCO₂ gap, also known as P(V-A)CO₂ and delta PCO₂ or ∆PCO₂) has been established as a sensitive marker of tissue perfusion and CO adequacy in septic shock but lacks extensive exploration in CS.

This narrative review evaluates the possible uses of V-A PCO₂ gap in contemporary management of CS. Based on the available literature, it elucidates how the V-A PCO₂ gap may offer valuable insight into tissue perfusion and CO adequacy in patients with CS. Elevated V-A PCO₂ gaps may reflect impaired clearance of CO₂ due to reduced CO and tissue hypoxia, serving as a reliable early indicator of circulatory failure. Integrating V-A PCO₂ gap monitoring into contemporary hemodynamic assessments holds potential to improve clinical decision-making, enabling more timely interventions and better stratification of patients at risk of deterioration.

The sparse evidence suggests an association between elevated V-A PCO₂ gaps and poor outcomes in cardiac patients, including increased mortality and prolonged ventilation needs. Further research is needed to validate the use of this marker in CS and explore its potential to enhance treatment protocols by providing a more nuanced understanding of tissue-level perfusion, especially when macrocirculatory function appears normalized.

{"title":"Can utilization of the venous-to-arterial carbon dioxide difference improve patient outcomes in cardiogenic shock? A narrative review","authors":"Oskar Kjærgaard Hørsdal","doi":"10.1016/j.ahjo.2025.100504","DOIUrl":"10.1016/j.ahjo.2025.100504","url":null,"abstract":"<div><div>Cardiogenic shock (CS) is a critical condition with high mortality, characterized by reduced cardiac output (CO) and tissue hypoperfusion, despite advancements in treatment. Traditional hemodynamic markers like CO measurements, monitoring of mixed venous oxygen saturation (SvO₂) and lactate levels have limitations, particularly in detecting microcirculatory dysfunction. The venous-to-arterial carbon dioxide tension difference (V-A PCO₂ gap, also known as P(V-A)CO<sub>2</sub> and delta PCO<sub>2</sub> or ∆PCO<sub>2</sub>) has been established as a sensitive marker of tissue perfusion and CO adequacy in septic shock but lacks extensive exploration in CS.</div><div>This narrative review evaluates the possible uses of V-A PCO₂ gap in contemporary management of CS. Based on the available literature, it elucidates how the V-A PCO<sub>2</sub> gap may offer valuable insight into tissue perfusion and CO adequacy in patients with CS. Elevated V-A PCO₂ gaps may reflect impaired clearance of CO₂ due to reduced CO and tissue hypoxia, serving as a reliable early indicator of circulatory failure. Integrating V-A PCO₂ gap monitoring into contemporary hemodynamic assessments holds potential to improve clinical decision-making, enabling more timely interventions and better stratification of patients at risk of deterioration.</div><div>The sparse evidence suggests an association between elevated V-A PCO₂ gaps and poor outcomes in cardiac patients, including increased mortality and prolonged ventilation needs. Further research is needed to validate the use of this marker in CS and explore its potential to enhance treatment protocols by providing a more nuanced understanding of tissue-level perfusion, especially when macrocirculatory function appears normalized.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"50 ","pages":"Article 100504"},"PeriodicalIF":1.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143172988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cultivating a thriving environment for women in cardiology through leadership and inclusion

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-01 DOI: 10.1016/j.ahjo.2025.100500

Renée P. Bullock-Palmer , Martha Gulati , Gina Lundberg , Monika Sanghavi , Odayme Quesada , Nosheen Reza , Julia Grapsa , Jessica Lee , Annabelle Santos Volgman , Laxmi Mehta , Sandra J. Lewis , Kamala P. Tamirisa

引用次数: 0

Patients' lives don't pause for blanking periods

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice

Pub Date : 2025-02-01 DOI: 10.1016/j.ahjo.2024.100497

Mohammed Ruzieh , John M Mandrola , Andrew J Foy

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

American heart journal plus : cardiology research and practice

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀